Cytokinetics Incorporated Common Stock (CYTK)

FairStock Score: 17/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Cytokinetics first through Graham’s test of demonstrated earnings and margin of safety, and the company does not yet pass. At the $60.73 close on 2026-10-26, the $8.4 billion market cap sits against trailing EPS of -$7.22 and a FairStock-calculated P/E of -8.41. Cytokinetics lost $198.8 million in fiscal Q2 2026, the quarter ended 2026-06-30, on $28.6 million of revenue; fiscal Q1 2026 lost $206.0 million on $19.4 million. Full-year fiscal 2025 revenue was $88.0 million against a $785.0 million net loss, while fiscal 2024 revenue was $18.5 million against a $589.5 million loss. Revenue is growing, but from a very small base. Trailing free cash flow is -$580.7 million, equal to a FairStock-calculated FCF yield of -6.9% on the market cap. The risk markers are not comforting: FairStock-calculated Piotroski 4/9 and Altman -0.05. The business does have a marketed product, MYQORZO, plus aficamten and omecamtiv in development, so there is real operating substance. Still, it is not self-funding today. I would need to see product revenue scale, losses narrow from the Q2 2026 level, and cash burn improve before this looks like a value bargain rather than a speculative biotech bet. The FairStock score of 17/100 captures that gap.

In plain English: Cytokinetics is a drug company that sells MYQORZO for a heart condition and is developing other muscle medicines. Sales are rising, but the company still loses very large amounts of money and spends more cash than it brings in, so the business looks financially weak today. At the $60.73 close on 2026-10-26, it is hard to call the stock cheap or expensive using normal profit measures because there are no profits; the numbers point to a risky, early-stage commercial company rather than a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer